X0609 4 2026-07-14 0002012593 Rapport Therapeutics, Inc. RAPP 0001722140 Ceesay Abraham false RAPPORT THERAPEUTICS, INC. 99 HIGH STREET, SUITE 2100 BOSTON MA 02110 true true false false Chief Executive Officer true Common Stock 2026-07-14 4 S false 5481 39.7217 D 542546 D Common Stock 2026-07-14 4 S false 2729 40.5724 D 539817 D Common Stock 81729 I By Ceesay Family Irrevocable Trust Common Stock 20729 I By Dorothy Ceesay Irrevocable Trust These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Shares held by The Ceesay Family Irrevocable Trust u/t/d March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose. /s/ Troy Ignelzi, Attorney-in-Fact 2026-07-15